Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension.

Schwartz GF, Reardon G.

Surv Ophthalmol. 2004 Nov-Dec;49(6):621-3; author reply 623-4. No abstract available.

PMID:
15530957
2.
3.

The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries.

Holmstrom S, Buchholz P, Walt J, Wickstrøm J, Aagren M.

Curr Med Res Opin. 2006 May;22(5):897-905.

PMID:
16709311
4.
5.

Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.

Kymes S.

Am J Ophthalmol. 2006 Aug;142(2):354; author reply 354-5. No abstract available.

PMID:
16876536
6.

A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension.

Day DG, Schacknow PN, Sharpe ED, Ellyn JC, Kulze JC 3rd, Threlkeld AB, Jones ED, Brown RH, Jenkins JN, Stewart WC.

J Ocul Pharmacol Ther. 2004 Oct;20(5):383-92.

PMID:
15650513
8.

Comments on The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries.

Soto J.

Curr Med Res Opin. 2006 Oct;22(10):1899-901; author reply 1901-2. No abstract available.

PMID:
17022847
9.
10.

A cost-effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: a European perspective.

Hommer A, Wickstrøm J, Friis MM, Steeds C, Thygesen J, Ferreras A, Gouws P, Buchholz P.

Curr Med Res Opin. 2008 Apr;24(4):1057-63. doi: 10.1185/030079908X280626 .

PMID:
18315942
11.

Treatment of glaucoma in clinical practice: four-year results from a patient registry in France.

Kobelt G, Texier-Richard B, Buchholz P, Bron A, Renard JP, Rouland JF, Nordmann JP.

J Glaucoma. 2010 Mar;19(3):199-206. doi: 10.1097/IJG.0b013e3181af31d6.

PMID:
19661825
12.

Cost-offset analysis: bimatoprost versus other prostaglandin analogues in open-angle glaucoma.

Berenson KL, Kymes S, Hollander DA, Fiscella R, Burk C, Patel VD.

Am J Manag Care. 2011 Sep 1;17(9):e365-74.

13.

[The more favourable cost/effectiveness ratio of latanoprost vs bimatoprost and travoprost when using normally for treatment of glaucoma].

Soto J.

Arch Soc Esp Oftalmol. 2005 Jan;80(1):9-10; author reply 10. Spanish. No abstract available.

PMID:
15692888
14.

Bimatoprost: a pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension.

Plosker GL, Keam SJ.

Pharmacoeconomics. 2006;24(3):297-314. Review.

PMID:
16519552
15.

Latanoprost versus bimatoprost.

Eisenberg D.

Ophthalmology. 2003 Sep;110(9):1861-2; author reply 1862. No abstract available.

PMID:
13129903
16.
17.

Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France.

Bernard LM, Althin R, Dhawan R, Grima DT, Lam A, Aballéa S.

Eur J Ophthalmol. 2003 Jul;13 Suppl 4:S30-43.

PMID:
12948051
18.
19.

Refill rates and budget impact of glaucoma lipid therapy: a retrospective database analysis.

Walt JG, Wilensky JT, Fiscella R, Chiang TH, Guckian A.

Clin Drug Investig. 2007;27(12):819-25.

PMID:
18020539
20.

Comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study.

Noecker RS, Dirks MS, Choplin N; Bimatoprost/Latanoprost Study Group..

Am J Ophthalmol. 2004 Jan;137(1):210-1; author reply 211-2. No abstract available.

PMID:
14700685
Items per page

Supplemental Content

Support Center